A potential coronavirus vaccine has been greenlighted for clinical trials. The candidate aims to deliver the same efficacy as Pfizer’s shots, but without the subzero cold storage requirement. Learn more at https://www.deccanherald.com/national/covid-19-indias-mrna-vaccine-receives-approval-for-human-trial-925865.html.
Affordable Easy To Store COVID-19 Vaccines
By US Company Goes On Human Trials
As we've all observed the past
few months, when it comes to
the choice of a COVID-19
vaccine, there are factors to
consider aside from efficacy.
HDT Bio, a biotech startup based in
Seattle, has just announced that their
COVID-19 vaccine candidate has been
approved for clinical trials in India. The
research organization utilizes a next-
generation vaccine platform funded by
Zoic Capital.
The latest announcement
brings HDT Bio’s vaccine
one step closer to mass
inoculation.
To produce the shots, HDT Bio is using a
more recent technology called mRNA, which
is expected to yield the same efficacy rate
as Pfizer’s vaccine. Relative to the more
popular brand, however, the vaccine in
development costs less to manufacture and
does not use raw materials.
Another benefit of HDT Bio’s
product is it does not require
extremely cold temperatures
for storage and transport.
Instead of -70 degrees Celsius, the shots are
designed to remain stable between just 2 to 8
degrees Celsius. This presents a significant
advantage when it comes to dose
administration, especially in countries and
remote locations where access to specialized
storage equipment is limited.
Compared to conventional
vaccines, HDT Bio’s mRNA
vaccine can be developed
within a shorter time frame as it
does require a bacterial host to
grow.
With all these characteristics, the
product is expected to offer a
highly scalable and cost-effective
immunization solution once it has
been greenlighted for public use.
HDT Bio specializes in research geared
toward the prevention, detection, and
treatment of various diseases. Their
efforts have recently enabled them to
design several technologies with the
ability to synthesize the genetic material
of viruses.
HDT Bio’sCOVID-19 vaccine
research, along with their other
projects, are in keeping with their
mission of helping the world
overcome constraints to disease
treatment supply and access.
Learn more at
www.hdt.bio
By US Company Goes On Human Trials
As we've all observed the past
few months, when it comes to
the choice of a COVID-19
vaccine, there are factors to
consider aside from efficacy.
HDT Bio, a biotech startup based in
Seattle, has just announced that their
COVID-19 vaccine candidate has been
approved for clinical trials in India. The
research organization utilizes a next-
generation vaccine platform funded by
Zoic Capital.
The latest announcement
brings HDT Bio’s vaccine
one step closer to mass
inoculation.
To produce the shots, HDT Bio is using a
more recent technology called mRNA, which
is expected to yield the same efficacy rate
as Pfizer’s vaccine. Relative to the more
popular brand, however, the vaccine in
development costs less to manufacture and
does not use raw materials.
Another benefit of HDT Bio’s
product is it does not require
extremely cold temperatures
for storage and transport.
Instead of -70 degrees Celsius, the shots are
designed to remain stable between just 2 to 8
degrees Celsius. This presents a significant
advantage when it comes to dose
administration, especially in countries and
remote locations where access to specialized
storage equipment is limited.
Compared to conventional
vaccines, HDT Bio’s mRNA
vaccine can be developed
within a shorter time frame as it
does require a bacterial host to
grow.
With all these characteristics, the
product is expected to offer a
highly scalable and cost-effective
immunization solution once it has
been greenlighted for public use.
HDT Bio specializes in research geared
toward the prevention, detection, and
treatment of various diseases. Their
efforts have recently enabled them to
design several technologies with the
ability to synthesize the genetic material
of viruses.
HDT Bio’sCOVID-19 vaccine
research, along with their other
projects, are in keeping with their
mission of helping the world
overcome constraints to disease
treatment supply and access.
Learn more at
www.hdt.bio